Sign in to fuzzto save your conversations, follow your research and come back anytime.
Goldline Pharmaceutical
| Metric (₹ crore) | Q3 FY26 | Q4 FY26 |
|---|---|---|
| Sales | 7.51 | 9.79 |
| Expenses | 5.99 | 7.01 |
| EBITDA | 1.52 | 2.78 |
| Depreciation | 0.06 | 0.06 |
| EBIT | 1.46 | 2.72 |
| Interest | 0.3 | 0.35 |
| Profit Before Tax | 1.16 | 2.37 |
| Net Profit | 0.87 | 1.89 |
| EPS | 1 | 2.18 |
| Metric (₹ crore) | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Operating Cash Flow | 2.39 | 2.92 | 3.18 | 2.81 |
| Investing Cash Flow | -1.04 | -1.11 | 0.16 | -0.06 |
| Financing Cash Flow | -1.44 | -1.08 | -2.89 | -3.4 |
| Net Cash Flow | -0.09 | 0.73 | 0.45 | -0.65 |
| Metric (₹ crore) | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Equity / Shareholders' Funds | 5.89 | 7.87 | 10.35 | 14.25 |
| Total Liabilities | 13.5 | 15.07 | 15.93 | 14.62 |
| Total Assets | 19.39 | 22.93 | 26.28 | 28.87 |